Transgenic Group (2342) · InitiativeAchieved
Strategic Focus and Concentration in the Drug Discovery Support Business through the Transfer of ジェネティックラボ
First written in FY2022-Q3. 1 of 2 entries say "Achieved", first in FY2023-Q1. Latest entry: FY2023-Q1.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Removal from the Scope of Consolidation Through the Transfer of Shares in a SubsidiaryA theme 307 companies write about · 44 as a headwind · 217 as a tailwind
56 other companies' latest entry also says "Achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 156 companies compared. The sentences above are computed from all 156.Comparing 200 of the theme's 389 threads.Full recordFilings, disclosures and news, newest first
- FY2023-Q1AchievedAnnual report
「During the nine-month period ended in the current first quarter, all shares of 株式会社ジェネティックラボ were transferred in January 2022, resulting in」
The transfer of all shares of ジェネティックラボ, decided in FY2022-Q3, was executed in January 2022, moving the selection and concentration of the drug discovery support business to the implementation stage. - FY2022-Q3First statedAnnual report
「Following careful consideration of the continued enhancement of the Group’s corporate value and the selection and concentration of its drug discovery support businesses, the Company resolved to transfer all shares of ジェネティックラボ to Eurofins Clinical Testing Japan Holding 株式会社, a subsidiary of the Eurofins group, on 10 December 2021, in order to enable the Group and 株式会社ジェネティックラボ to develop in new stages.」
The Company decided to transfer all shares of ジェネティックラボ to select and concentrate its drug discovery support businesses and continuously enhance corporate value. The contract date was 10 December 2021, the transfer execution date was 1 January 2022, and the provisional transfer price was ¥3,212 million. A gain on the sale of shares in an affiliated company of approximately ¥1,450 million was expected.